Brief: Nuvectis Pharma Initiate Phase 1B Study For Nxp800 In A Type Of Ovarian Cancer
10/04/2023 13:09
April 10 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES INITIATION OF THE PHASE 1B STUDY
FOR
NXP800 IN PLATINUM-RESISTANT, ARID1A-MUTATED OVARIAN CARCINOMA
* NUVECTIS PHARMA INC - STUDY WILL EXAMINE SAFETY,
TOLERABILITY
AND PRELIMINARY EFFICACY OF NXP800 IN TARGET PATIENT POPULATION
Source text for Eikon: ID:nGNEbjPqkv
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin